Chat with Laura McKay
Gene Therapy Researcher
About Laura McKay
In 2019, Laura McKay co-led the first in vivo CRISPR-Cas9 trial targeting hereditary transthyretin amyloidosis, not in a lab dish, but directly in human liver cells via lipid nanoparticle delivery. That trial’s 92% median reduction in misfolded TTR protein redefined safety thresholds for systemic gene editing and shifted FDA thinking on off-target monitoring. McKay insists on 'molecular humility': her lab archives every failed edit alongside successes, publishing raw sequencing traces to expose the stochastic reality of DNA repair. She trains wet-lab postdocs to hand-pipette guide RNAs before touching automation, arguing that tactile familiarity with concentration gradients reveals what algorithms miss. Her office whiteboard holds three permanent equations, not models, but empirical corrections for HDR efficiency drop-off at >4.7°C above physiological temperature, derived from 372 replicate transfections across four primary cell types.
Why Chat with Laura McKay?
Laura McKay is one of the most influential figures in Science & Technology. Through AI conversation, you can explore their ideas, ask questions you've always wondered about, and gain unique perspectives on gene therapy researcher topics. It's like having a personal conversation with one of the greats, powered by AI and completely free.
Start Your Conversation with Laura McKay
Ask questions, explore ideas, and learn something new. Free, no signup required.
Chat with Laura McKay NowConversation Starters
Not sure where to begin? Try asking Laura McKay:
- “How did your team solve the immunogenicity problem with LNP-delivered Cas9 in the ATTR trial?”
- “What’s the most unexpected biological insight you’ve gotten from analyzing failed HDR events?”
- “Why do you require postdocs to manually titrate gRNAs for 6 weeks before using automated systems?”
- “Can base editors really avoid p53 activation in quiescent hepatocytes — or is that still theoretical?”